Milestone Pharmaceuticals (MIST) Net Cash Flow (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Net Cash Flow came in at -$1.7 million in Q1 2026, down 108.75% YoY from $19.8 million in Q1 2025, and down 106.56% on a QoQ basis from $26.4 million in Q4 2025.
Milestone Pharmaceuticals (MIST) Net Cash Flow (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Net Cash Flow data on file, last reported at -$1.7 million in Q1 2026.
- Quarterly Net Cash Flow fell 108.75% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.2 million (down 24.95% YoY) and the FY2025 annual result came in at $47.7 million, up 313.12% from the prior year.
- Net Cash Flow fell to -$1.7 million in Q1 2026, from $26.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $66.3 million in Q1 2023 to a low of -$41.4 million in Q2 2023.
- A 5-year average of -$2.5 million and a median of -$1.7 million in 2026 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow slumped 4755.88% — and 2025, when it soared 1004.1%.
- Tracing MIST's Net Cash Flow over 5 years: stood at -$29.6 million in 2022, then jumped by 113.09% to $3.9 million in 2023, then jumped by 222.47% to $12.5 million in 2024, then jumped by 110.64% to $26.4 million in 2025, then sank by 106.56% to -$1.7 million in 2026.
- The last three Net Cash Flow figures came in at -$1.7 million (Q1 2026), $26.4 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Milestone Pharmaceuticals | 42.70 Mn | -128.80 Mn | - | 98.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98.41 Mn |
| Jun 30, 2026 | 98.41 Mn |
| Mar 31, 2026 | -1.73 Mn |
| Mar 31, 2026 | -1.73 Mn |
| Dec 31, 2025 | 26.36 Mn |
| Dec 31, 2025 | 26.36 Mn |
| Sep 30, 2025 | 4.19 Mn |
| Sep 30, 2025 | 4.19 Mn |
| Jun 30, 2025 | -2.59 Mn |
| Jun 30, 2025 | -2.59 Mn |
| Mar 31, 2025 | 19.77 Mn |
| Mar 31, 2025 | 19.77 Mn |
| Dec 31, 2024 | 12.52 Mn |
| Dec 31, 2024 | 12.52 Mn |
| Sep 30, 2024 | -463,000.00 |
| Sep 30, 2024 | -463,000.00 |
| Jun 30, 2024 | 3.13 Mn |
| Jun 30, 2024 | 3.13 Mn |
| Mar 31, 2024 | -3.63 Mn |
| Mar 31, 2024 | -3.63 Mn |